**FOI Ref: 6325**

**Category(ies): Clinical - Drugs**

**Subject: Metastatic/Breast Cancer Patients**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
* Abemaciclib (Verzenios) + aromatase inhibitor \*
* Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
* Alpelisib (Piqray) + Fulvestrant (Faslodex)
* Atezolizumab (Tecentriq)\*\*
* Bevacizumab (Avastin)
* Eribulin (Halaven)
* Everolimus (Afinitor) + Exemestane
* Fulvestrant (Faslodex) as a single agent
* Gemcitabine + paclitaxel
* Herceptin (Trastuzumab) + paclitaxel
* Herceptin (Trastuzumab) as a single agent
* Lapatinib (Tyverb)
* Neratinib (Nerlynx)
* Olaparib (Lynparza)
* Palbociclib (Ibrance) + aromatase inhibitor\*
* Palbociclib (Ibrance) + Fulvestrant (Faslodex)
* Pertuzumab (Perjeta) + trastuzumab + docetaxel
* Ribociclib (Kisqali) + aromatase inhibitor\*
* Ribociclib (Kisqali) + Fulvestrant (Faslodex)
* Talazoparib (Talzenna)
* Trastuzumab emtansine (Kadcyla)
* Other active systemic anti-cancer therapy \*\*

\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent | Systemic Anti-Cancer Therapy for Breast cancer patients is delivered by Weston Park; therefore, we are unable to answer this request. The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at sth.foi@nhs.net  |
| Q2. For the above patients, how many of these received their first ever dose for each product line? |  |